FDA Approval Summary: Belzutifan for VHL Disease Tumors-Letter.

Trinh, Jonathan Q; Ellithi, Moataz; Shonka, Nicole; Bergan, Raymond C

Trinh, Jonathan Q; Ellithi, Moataz; Shonka, Nicole; Bergan, Raymond C.

Affiliation

Trinh JQ; Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Ellithi M; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.
Shonka N; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.
Bergan RC; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.

Clin Cancer Res ; 29(3): 684, 2023 02 01.

Article in En | MEDLINE | ID: mdl-36722140

Subject(s)

Von Hippel-Lindau Tumor Suppressor Protein; Humans; Von Hippel-Lindau Tumor Suppressor Protein/genetics

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Von Hippel-Lindau Tumor Suppressor Protein Limits: Humans Language: En Journal: Clin Cancer Res Year: 2023 Document type: Article

Fulltext

XML

PubMed Links

Search on Google